AstraZeneca DESTINY-PanTumor02 (HER2+ Tumors)
What is the Purpose of this Study?
-Have an infusion of the study drug (trastuzumab deruxtecan) once every 3 weeks
-Provide old tumor tissue
-Have an eye exam
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)
Who Can Participate in this Study?
Adults with the following advanced solid tumors that express HER2
-Biliary tract cancer
-Rare tumors (excluding breast, non-small cell lung cancer, gastric cancer, and colorectal cancer
What is Involved?
We are doing this research study to understand the effectiveness and safety of trastuzumab deruxtecan (T-DXd) on select HER2-expressing tumors (tumors that have a specific protein on their surface).